Navigation Links
Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
Date:3/8/2011

USDProduct revenue

545,174

587,368

88,9951,843,685

2,125,977

322,118Other revenue

1,279

365

5513,386

15,121

2,291Total revenue546,453587,73389,0501,857,0712,141,098324,409Cost of materials and production

(89,468)

(93,244)

(14,128)(320,945)

(341,787)

(51,786)Gross profit456,985494,48974,9221,536,1261,799,311272,623Operating expenses:Research and development

(50,129)

(31,448)

(4,765)(132,981)

(125,737)

(19,051)Sales, marketing and distribution

(299,890)

(330,608)

(50,092)(1,002,419)

(1,186,144)

(179,719)General and administrative

(56,339)

(69,617)

(10,548)(222,118)

(269,512)

(40,835)Impairment loss on goodwill

(76,398)--(76,398)--Income (loss) from operations(25,771)62,8169,517102,210217,91833,018Interest income

1,458

1,010

1538,861

4,214

638Interest expense

(3,446)

(5,465)

(828)(12,126)

(19,920)

(3,018)Foreign currency exchange gains

32

1,877

284382

5,511

835Other income

1,880

136

212,971

2,286

346Equity in losses of equity method affiliated
companies

(56,532)

(3,479)

(527)(56,532)

(14,716)

(2,230)Earnings (loss) before income taxes (82,379)56,8958,62045,766195,29329,589Income tax expense

(8,066)

6,834

1,035(16,897)

(10,640)

(1,612)Net Income(loss)(90,445)63,7299,65528,869184,65327,977Less: Net (income) loss attributable to the
noncontrolling interest

15,028

(5,033)

(763)(2,441)

(12,242)

(1,855)Net income (loss) attributable to Simcere(75,417)58,6968,89226,428172,41126,122E'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
2. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
3. Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
4. Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
5. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
6. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
7. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
8. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
9. Simceres Diosmectite API Passes EU-GMP Inspection
10. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
11. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014  Abaxis, Inc. ... manufacturing point-of-care blood instrumentation and consumables to the medical, ... Severson , Chairman and Chief Executive Officer, will present ... Ideas Conference 2014 on Tuesday, September 9, 2014 at ... the Omni Berkshire Place Hotel in New ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
(Date:8/28/2014)... WILMINGTON, Del. , Aug. 28, 2014  Rigrodsky & Long, ... shares of Lannett Company, Inc. (NYSE: LCI )? , ... between September 10, 2013 and July 16, 2014, inclusive? , ... Inc.? , Do you want to discuss your rights? ... former Special Assistant United States Attorney, Timothy J. MacFall , ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... HANOVER, N.J., Dec. 6, 2010 The Novartis ... demonstrated substantial disease control and tumor reduction in ... or had become refractory after an autologous stem ... Phase II clinical trial presented today(1). ...
... 6, 2010 Wells Fargo Practice Finance, formerly known ... preferred provider for optometric practice and equipment financing for ... affinity relationship through the AOA,s Member Advantage Program will ... for practice acquisition, start-up and expansion projects, along with ...
Cached Medicine Technology:Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 2Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 3
(Date:8/31/2014)... With the NCAA set to undergo ... an interview with Yale University Associate Athletic Director Steve ... approach to ensuring student-athlete experience that is consistent with ... a number of key factors that contribute to a ... factor in creating this culture seems simple at first. ...
(Date:8/31/2014)... tea reduces non-cardiovascular mortality by 24%, reveals a study ... by Professor Nicolas Danchin from France. , Professor Danchin ... coffee it,s probably better to drink tea. Coffee and ... Their effects on cardiovascular (CV) health have been investigated ... the effects of coffee and tea on CV mortality ...
(Date:8/30/2014)... Barcelona, Spain Sunday 31 August 2014: A ... and safe in a real world setting, according ... by Dr Stylianos Pyxaras from Germany. The direct ... features that improve operator control and has the ... outcomes in patients with severe aortic stenosis. , ...
(Date:8/30/2014)... 31, 2014 Not only is USHEALTH Advisors ... has just recorded its highest level of late-summer sales, including ... company is going to set a new record in 2014,” ... “Our growth in both weekly annualized volume and the ... last week of August, we saw even more of our ...
(Date:8/30/2014)... Zensah®, the leader in compression technology and comfort, ... a best-seller within golf and tennis. Golfers and tennis players ... most by using the compression elbow sleeve to help treat ... condition that causes pain on the inner side of your ... the bony bump on the inside of your elbow. The ...
Breaking Medicine News(10 mins):Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2Health News:USHEALTH Advisors, LLC Continues Its Record-Setting Sales Pace 2Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2
... are less likely to develop high blood pressure say researchers ... the study researchers analyzed data from two large studies, which ... women questionnaires, which asked about their folate and supplemental folic ... at the start of the study. It was found that ...
... suggest people who carry a gene that produces a ... small increased risk for stroke.// ,Researchers reviewed medical ... found that previous study results were observational in nature. ... confounding factors by looking at data on the link ...
... a recent study researchers have linked breathing cancer-causing compounds ... cancer among offspring. They also believe that nearly all ... mother’s inhalation of noxious substances. ,The study compared ... and younger who died from leukemia and other cancers ...
... Men who receive a common therapy after prostate cancer surgery ... based on // findings of a recent study. For ... therapy suffered a broken bone within five years of diagnosis, ... receive the treatment. ,Androgen-deprivation therapy has traditionally been given ...
... Several studies have linked the use of estrogen replacement therapy ... mineral density( BMD ) is known as a good indicator ... men to determine how BMD related to the risk of ... decline at the beginning of the study. Researchers then measured ...
... Previous studies have shown inhaled corticosteroids can reduce the ... However, results from a study conducted by researchers from ... more than 2,650 patients with COPD who were prescribed ... 90-day period. Nearly 5,400 patients who had never used ...
Cached Medicine News:
Illuminated Phoroptor Refracting Instrument. Illumination is provided by a cool-running, energy efficient LEDs (Light Emitting Diodes) that light only what you need to see without affecting the darke...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
Red Lens Maddox...
Maddox Rod, short handle (12cm)...
Medicine Products: